Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615006 | 0.91 | MRGPRX4 (0.46) | TTRPLA2G2DMRGPRX4SLC16A3RORC | |
| SCHEMBL10064017 | 0.89 | SLC22A12 (0.39) | PLA2G2DMRGPRX4SLC16A3SLC22A12CNR2 | |
| SCHEMBL10064303 | 0.88 | LMNA (0.45) | MRGPRX4ALDH1A1HPGD | |
| SCHEMBL10063691 | 0.87 | CSNK2A2 (0.41) | TTRPLA2G2DMRGPRX4SLC16A3SLC22A12 | |
| SCHEMBL10063756 | 0.87 | SLC22A12 (0.48) | PLA2G2DSLC22A12ALDH1A1HPGDKDM1A | |
| SCHEMBL7920119 | 0.86 | PLA2G2D (0.44) | TTRPLA2G2DMRGPRX4SLC16A3SLC22A12 | |
| SCHEMBL618435 | 0.85 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL10064020 | 0.85 | MRGPRX4 (0.39) | PLA2G2DMRGPRX4SLC22A12CNR2ALDH1A1 | |
| SCHEMBL615319 | 0.83 | HTR5A (0.53) | — | |
| SCHEMBL10063771 | 0.82 | SLC22A12 (0.44) | SLC22A12ALDH1A1HPGDGRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2394988-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | TTR 2555/4885PLA2G2D 1120/4885MRGPRX4 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.